![\"How](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/10\/How-the-Cure-for-Herpes-Became-Mired-in-Controversy.jpg\" "\\"How")
<\/p>\nOver several decades, the Food and Drug Administration (FDA) has gone to great lengths to maintain its longstanding relationship with major pharmaceutical companies, namely by approving numerous medications.\u00a0 (Many of those approvals, for prescription medicines like Isotretinoin, Pemoline, and Propoxyphene, were eventually recalled after causing patient deaths or irreversible damage.)\u00a0 And this dynamic hasn\u2019t been limited to medical treatments.\u00a0 Despite extensive research that shows sugar is the leading cause of heart disease and diabetes, the FDA has gone so far as to endorse it, fearing the ramifications that a warning label could have on agriculture producers and the greater food production industry.\u00a0 Given these historical patterns, it comes as no surprise that the FDA is opposed to natural medicine, especially when alternative treatments threaten to cut into pharmaceutical companies\u2019 market share.<\/p>\n
<\/p>\n
Synergy Pharmaceuticals is one such company currently facing pushback from the FDA. Its name is a bit confusing considering that its catalog features only natural vitamins. Even more confusing is that there are two companies sharing the name. The New York-based Synergy Pharmaceuticals went bust in 2016, while Synergy Pharmaceuticals Australia stayed in business. Yet the Australian company has still been linked to controversy and supply concerns from its onset.<\/p>\n
In November 2020, Synergy Pharmaceuticals Australia did shut down temporarily after facing COVID-19-related supply chain issues.\u00a0 Thankfully, after a change of ownership in May 2021, the company resumed operations.<\/p>\n
However, it\u2019s Synergy\u2019s most high-profile product that has generated controversy, not its most recent business troubles. The company bills itself as the producer of the world\u2019s first cure for the herpes simplex virus. This claim has, unsurprisingly, attracted an incredible amount of critique and cynicism.\u00a0 But the degree to which the naysayers, the pharmaceutical industry, and conventional medicine practitioners have scrutinized Synergy\u2019s treatment is nearly insurmountable.\u00a0 In any other scenario, one would consider such a development a monumental leap forward in herpes sufferers\u2019 fight against the virus.\u00a0 Instead, Synergy Pharmaceuticals has found itself in the center of a vicious battle, spearheaded by proponents of conventional medicine.<\/p>\n
Their pushback is in opposition to the treatment\u2019s proven success.\u00a0 In reviewing online feedback and forum discussions to date, there\u2019s a contingent of patients who have clearly been cured and who can vouch for the treatment\u2019s ability to eradicate the virus.\u00a0 Still, there are just as many who refute the treatment\u2019s effectiveness. Those in the latter camp are mostly individuals who haven\u2019t used the treatment but feel strongly that natural medicine is incapable of curing any virus.\u00a0 In the views of those who are opposed, they would only trust their local doctor or a more conventional medical institution to validate a cure.\u00a0 Their resistance is na\u00efve, as more than 40% of pharmaceutical drugs are derived from plants.\u00a0 For example, penicillin was created from Penicillium chrysogenum, a species of fungus that is essentially mold.\u00a0 Morphine is crafted from opium poppies, aspirin from willow bark, and so on.\u00a0 Natural and conventional medicines have far more in common than many people realize, including those waging the battle against Synergy Pharmaceuticals.<\/p>\n
To investigate, we compared the effectiveness of Synergy\u2019s treatment to that of Acyclovir, the most commonly used suppressant medication for herpes patients.\u00a0 The most startling difference between the two treatments was that Acyclovir had to be used every day to suppress herpes outbreaks or cold sores.\u00a0 The medication didn\u2019t provide a long-term solution unless it was administered regularly, and even then, it had only a modest rate of actually stopping outbreaks from occurring.\u00a0 By comparison, Synergy\u2019s product reduced herpes outbreaks and cold sores permanently.\u00a0 In one independent study, those who\u2019d suffered frequent outbreaks on a monthly or bimonthly basis went on to have no further outbreaks or just one or two outbreaks per year.\u00a0 These results were measured post-treatment once the person had completed a six-month clinical trial.\u00a0 These findings suggest that the treatment\u2019s benefit remained intact for patients after the protocol was finished.<\/p>\n
Furthermore, one only needs to assess the long list of Acyclovir side effects to determine whether it\u2019s worth the financial outlay and health implications.\u00a0 Given that Synergy\u2019s natural product has the potential for only a handful of mild side effects and costs far less, explaining the difference between the two products is like comparing apples to oranges.<\/p>\n
From an external perspective, however, Synergy has clearly been unable to capitalize on its product\u2019s ability to cure people of herpes due to what can only be described as poor marketing.\u00a0 This is understandable when taking into account that advertising via mainstream media or in medical centers is only permitted for drugs approved by the FDA.\u00a0 This amounts to a considerable shame, preventing people who are genuinely seeking help from accessing the product, due only to marketing limitations and the conventional medicine monopoly.\u00a0 To remedy this, Synergy conducted trials, and Yale students also carried out an independent study, all designed to determine if Synergy\u2019s product does what it claims to do.\u00a0 The results from both avenues of research supported the effectiveness of the product, showing that it achieved the unimaginable in clearing infected patients of the herpes simplex virus.\u00a0 The percentage rate certainly works in Synergy\u2019s favor, with an estimated 70% of trial subjects cured of herpes, but even having just 30% of participants cured would have been miraculous \u2013 it\u2019s something that has never been accomplished by any means, let alone a pharmaceutical-based medication.<\/p>\n
A groundbreaking innovation like Synergy\u2019s product, one that eases the suffering of herpes simplex virus patients, should be embraced, not shunned or chastised.\u00a0 And undoubtedly, Synergy has traveled down a rocky road in navigating the response to its discovery.\u00a0 But there is some hope that this product will become increasingly mainstream in the coming years.\u00a0 It may take some expansion into the European market, as well as greater investment.\u00a0 Both aspects could bring Synergy\u2019s vision to fruition, while also quieting some of the controversy and reducing the stigma associated with herpes.<\/p>\n
Though, to date, the ultimate takeaway is that changing the status quo \u2013 especially when it comes to shifting the way the medical community views natural medicine \u2013 is no easy task.<\/p>\n
Media contact<\/strong><\/p>\n Company:<\/strong> Synergy Pharmaceuticals Over several decades, the Food and Drug Administration (FDA) has gone to great lengths to maintain its longstanding relationship with major pharmaceutical companies, namely by approving numerous medications. (Many of those approvals, for prescription medicines like Isotretinoin, Pemoline, and Propoxyphene, were eventually recalled after causing patient deaths or irreversible damage.) And this dynamic hasn’t been […] Continue Reading
\nContact Name:<\/strong> Marcus Torres (Media and Public Relations Manager)
\nE-mail: <\/strong>Media@synergy-pharmaceuticals.com<\/a>
\nLocation: <\/strong>Collins Square Tower Five, 727 Collins Street, Melbourne, Victoria, 3008. Australia
\nWebsite:<\/strong> https:\/\/www.synergy-pharmaceuticals.com\/<\/a><\/p>\nTags:<\/b>
Reportedtimes<\/a>, IPS<\/a>, Content Marketing<\/a>, Menafn<\/a>, PR-Wirein<\/a>, Financial Content<\/a>, Extended Distribution<\/a>, iCN Internal Distribution<\/a>, English<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"